Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer

British Journal of Cancer

Volumn 91, Issue 8, 2004, Pages 1447-1452

  Saunders, H P ^a   Hogg, M ^a   Carrington, B ^a   Sjursen, A M ^a   Allen, J ^a   Beech, J ^a   Swindell, R ^a   Valle, J W ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

5 FU; CPT 11; Irinotecan; Lokich; Metastatic colorectal cancer

Indexed keywords

CIPROFLOXACIN; DEXAMETHASONE; FLUOROURACIL; IRINOTECAN; LOPERAMIDE; METOCLOPRAMIDE; ONDANSETRON; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FOLINIC ACID;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MALE; MAXIMUM PERMISSIBLE DOSE; METASTASIS; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; CANCER STAGING; COLORECTAL TUMOR; DOSE RESPONSE; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 7944239220     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602173     Document Type: Article

References (28)

1. Adam R (2003) Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 14(Suppl 2): ii13-ii16
2. Burris H, Kalman L, Bertoli L, Foulke R, Ratner L, Schwartzberg L, Weitberg A, Lokich J (2004) Continuous flat-dose capecitabine plus weekly irinotecan: an alternative first-line treatment for the treatment of metastatic colorectal cancer. Gastrointestinal Cancers Symposium, www.ASCO.org
3. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14: 709-715
4. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care vs supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418
5. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808-815
6. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047
7. Faivre J, Bader JP, Bertario L, Besbeas S, Castiglione G, Chamberlain J, Dubois G, Fric P, Gnauck R, Hardcastle J, Kewenter J, Kronborg O, Maltoni G, Wahrendork J (1995) Mass screening for colorectal cancer: statement of the European group for colorectal cancer screening. Eur J Cancer Prev 4: 437-439
8. Hale JP, Cohen DR, Maughan TS, Stephens RJ (2002) Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer. Br J Cancer 86: 1684-1690
9. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine vs intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase iii study. J Clin Oncol 19: 2282-2292
10. Kemeny NE (2000) Hepatic arterial therapy for the treatment of metastatic colorectal cancer. Semin Oncol 27: 126-131
11. Kemeny NE, Ron IG (1999) Hepatic arterial chemotherapy in metastatic colorectal patients. Semin Oncol 26: 524-535
12. Köhne CH, Van Cutsem E, Wils JA, Bokemeyer C, El-Serafi M, Lutz M, Lorenz MG, Anak O, Genicot B, Nordlinger B (2003) Irinotecan improves the activity of the aio regimen in metastatic colorectal cancer: results of the EORTC GI group study 40986. Proc Am Soc Clin Oncol 22, (abstract 1018)
13. Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, Cohen D, Hopwood P, Johnston C, Stephens RJ (2002) Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 359: 1555-1563
14. Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, McArdle C, Cain D, Stephens RJ (2003) Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 361: 457-464
15. Meta-analysis group in cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308
16. Nordlinger B, Rougier P (2002) Nonsurgical methods for liver metastases including cryotherapy, radiofrequency ablation, and infusional treatment: what's new in 2001? Curr Opin Oncol 14: 420-423
17. Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, Mailliard JA, Knost JA, Ghosh C, Kirschling RJ, Levitt R, Windschitl HE (1997) Phase ii trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15: 2910-2919
18. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer Jr E, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD (1999) A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85: 786-795
19. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801-3807
20. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251-260
21. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C (1998) Randomised trial of irinotecan vs fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407-1412
22. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343: 905-914
23. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL (2001) Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345: 144-145
24. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, Punt CJ, Alexopoulos CG, Dirix L, Symann M, Blijham GH, Cholet P, Fillet G, Van Groeningen C, Vannetzel JM, Levi F, Panagos G, Unger C, Wils J, Cote C, Blanc C, Herait P, Bleiberg H (1999) Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 35: 54-59
25. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106
26. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM (2001) Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 19: 1501-1518
27. Wiseman LR, Adkins JC, Plosker GL, Goa KL (1999) Oxaliplatin: a review of its use in the management of metastatic colorectal cancer. Drugs Aging 14: 459-475
28. Wiseman LR, Markham A (1996) Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 52: 606-623